Symphogen A/S, of Copenhagen, said the first patient was dosed in a phase I dose-escalation study of Sym015, a mixture of two antibodies targeting the MET receptor, in patients with solid tumors. An expansion cohort will follow in a subset patient population with a pre-identified gene signature.